Karathanasis, Schiemann lead team fighting breast cancer with nanotechnology and immunotherapy

Efstathios "Stathis” Karathanasis, PhD and William Schiemann, PhD are leading a team of researchers from the Case Comprehensive Cancer Center (Case CCC) and Duke University combining nanotechnology with immunotherapy to treat metastatic breast cancer. The team received a five-year, $3M grant from the National Cancer Institute to continue research into the engineering of nanoparticles that can wake up “cold” tumors so they can be located and attacked by the immune system.

The research team includes: Efstathios Karathanasis, PhD, an associate professor of biomedical engineering, Case Western Reserve University (CWRU) and member of the Cancer Imaging Program, Case CCC; William Schiemann, PhD, the Goodman-Blum Professor in Cancer Research, CWRU and member of the Molecular Oncology Program, Case CCC; Li Lily Wang, PhD, associate staff, Cleveland Clinic Lerner Research Institute and Member, Hematopoietic and Immune Cancer Biology Program, Case CCC; and Christopher Hoimes, MD, Duke University School of Medicine.

Read the full release